{"id":53508,"date":"2023-02-01T12:02:57","date_gmt":"2023-02-01T11:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/"},"modified":"2023-02-01T12:02:57","modified_gmt":"2023-02-01T11:02:57","slug":"orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/","title":{"rendered":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics"},"content":{"rendered":"
\n

OXFORD, England–(BUSINESS WIRE)–Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevica\u2019s development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics on receptor sets both novel and complimentary to its lead compound.\n<\/p>\n

<\/a><\/p>\n

\nEndevica\u2019s technology platform allows for the modification of peptides to modulate activity of GPCRs behind the blood-brain barrier. The focus of this agreement is to identify peptide hits from selected library populations, derived from Endevica\u2019s internal in silico<\/i> and modelling tools, which will be applied directly to Orbit\u2019s proprietary functional screening platform where agonism of proteins can be identified. The platform allows for millions of independent peptide sequences to be screened using a combination of bead-based DNA encoded libraries and microfluidic droplet screening. The peptide display engine is uniquely able to address soluble targets and targets in situ<\/i>, both on and in cells, allowing for significantly faster discovery times of relevant peptide leads based on affinity screens and\/or functional screens.\n<\/p>\n

\nThe agreement covers activities ranging from hit ID to development of cell-based assays, with an option for Endevica to further develop the peptide hits resulting from the screening activities.\n<\/p>\n

\nDr Neil Butt, Chief Executive Officer, Orbit Discovery, commented:<\/b> “This Agreement is further validation of the utility of Orbit\u2019s discovery platforms and adds to an expanding portfolio of partners obtaining benefit from our unique ability to screen so many peptides directly in cell based functional screens. Through these types of innovative collaborations, we play a critical role in accelerating the development of peptide therapeutics to potentially help people living with serious medical conditions<\/i>.” He added<\/b> \u201cOur aim is to make screening more relevant to the final biological read-outs required by drug developers, to ensure the right leads are selected first time, every time. This has the potential to deliver a generation of future therapeutics with high tissue specificity, low toxicity, and ultimately, safer and more effective medicines.\u201d<\/i>\n<\/p>\n

\nDr. Russell Potterfield, Chief Executive Officer & Executive Chairman, Endevica Bio, said: \u201c<\/b>Orbit has developed an impressive platform technology that is ideal for our requirements. We selected Orbit as our discovery partner for ongoing discovery work because of the team\u2019s experience in overcoming peptide screening challenges, alongside an industry-leading platform. The ability to identify functional hits to our targets using large libraries will be a more cost effective and speedier option to traditional discovery options. We are confident that the combination of Orbit\u2019s peptide discovery capabilities and our expertise in drug development will facilitate the accelerated entry of complimentary therapeutics portfolios into the clinic<\/i>.\u201d\n<\/p>\n

\nOrbit Discovery will be presenting at GPCRs-Targeted Drug Discovery Summit<\/a> at Hyatt Regency Boston, February 21-23 2023, Boston, MA.\n<\/p>\n

\nFor further information, please visit: https:\/\/www.orbitdiscovery.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nZyme Communications<\/b>
Lily Jeffery
\n
Tel: +44(0)7891 477 378
\n
Email: lily.jeffery@zymecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

OXFORD, England–(BUSINESS WIRE)–Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53508","6":"format-standard","7":"category-industry"},"yoast_head":"\nOrbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"OXFORD, England–(BUSINESS WIRE)–Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T11:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230201005470\/en\/1702313\/21\/high-res.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics\",\"datePublished\":\"2023-02-01T11:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/\"},\"wordCount\":528,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005470\\\/en\\\/1702313\\\/21\\\/high-res.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/\",\"name\":\"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005470\\\/en\\\/1702313\\\/21\\\/high-res.jpg\",\"datePublished\":\"2023-02-01T11:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005470\\\/en\\\/1702313\\\/21\\\/high-res.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005470\\\/en\\\/1702313\\\/21\\\/high-res.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics - Pharma Trend","og_description":"OXFORD, England–(BUSINESS WIRE)–Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-01T11:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230201005470\/en\/1702313\/21\/high-res.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics","datePublished":"2023-02-01T11:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/"},"wordCount":528,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005470\/en\/1702313\/21\/high-res.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/","url":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/","name":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005470\/en\/1702313\/21\/high-res.jpg","datePublished":"2023-02-01T11:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230201005470\/en\/1702313\/21\/high-res.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230201005470\/en\/1702313\/21\/high-res.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration-to-advance-development-of-cachexia-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53508"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53508\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}